Targeted organs | EV source | Modification | Therapeutic cargo | Injection method | Outcome | Refs. |
---|---|---|---|---|---|---|
Heart | CPCs | Transfection of miR-322 by electroporation after isolation of exosomes | miR-322 | Tail intravenous injection | CPC-EV loaded with miR-322 can treat ischemic cardiovascular disease | [134] |
BMSC | Transfection of Lamp-2b with IMTP plasmid | Targeting peptide IMTP | Intravenous injections | IMTP-EVs are more easily taken up by hypoxia-injured cells, improving myocardial function | [108] | |
CDCs | Transfection of Lamp-2b with CMP plasmid | Targeting peptide CMP | Intramyocardial injections and retroorbital intravenous injection | CMP-EVs improve selective targeting of ischemic heart tissue | [109] | |
BMSCs(with hypoxic conditions) | Combine with IMT peptides through bio-orthogonal chemistry | miR-125b-5p | Intravenously injection | Improve the targeting efficiency of EV, reduce cardiomyocyte apoptosis and reduce off-target | [135] | |
MSC | Platelet membranes to envelope EVs | – | Intravenous injections | Significantly increase the uptake of EVs by endothelial cells and cardiomyocytes, and reduce the phagocytosis of macrophages | [136] | |
Brain | MSC | Use click chemistry to couple functional ligands to the EV surface | Cur | Tail intravenous injection | cRGD-EV targets the ischemic brain injury area and inhibits inflammation and apoptosis in this area | [137] |
HEK 293Â T cell line | Transfection of RVG peptide plasmid and mu (MOR) siRNA into donor cells | MOR siRNA | Intravenously injected | RVG EVs encapsulating MOR siRNA cross the BBB and target the central nervous system to treat drug addiction | [138] | |
whole blood of SD rats | Coupling mAb GAP43 to the surface of Que-EV using the carbodiimide method | Quercetin | Tail intravenous injection | Que/mAb GAP43-EV enhances the accumulation of Que drugs at the site of cerebral ischemia injury and reduces the infarct size | [139] | |
Neutrophil | – | Dox | Intracardiac injection; intravenously injected | NEs-EVs carries Dox across the BBB to target brain tumors | [140] | |
Raw264.7 | Combine RGE peptides with EVs loaded with SPION and Cur by click chemistry | SPIONs and Cur | Tail intravenous injection | RGE-EV-SPION/Cur can cross the blood–brain barrier, accurately identify and treat gliomas | [110] | |
Lung | BMM | Combine the mixture of EVs and DSPE-PEG-AA using ultrasound and PTX | PTX | Tail intravenous injection | AA-PEG-EV specifically delivers PTX to lung metastases | [141] |
Bone | Dendritic cells | CAP-EV was synthesized by transfection of CAP-lamp2b plasmid | miR-140 | Intraarticular injection | CAP-EVs remain in the joint cavity, deliver miR-140 to deep cartilage regions, and alleviate OA progression | [25] |
Endothelial cells | – | miR-155 | Intraperitoneally injection | EC-EV is specifically taken up by BMMs, among which miR-155 inhibits osteoclast activity and reverses osteoporosis | [80] | |
NIH-3T3 cells | Plasmid transfection enables high expression of CXCR4 on the surface of EVs | Antagomir-188 | Tail intravenous injection | CXCR4-positive EVs could be recruited to the bone marrow | [79] | |
Skin | Human adipose tissue-derived mesenchymal stem cell | – | – | Intravenously or subcutaneously | Topical application | [142] |
Liver | MSC | The EVs modified with cationized pullulan | – | Tail intravenous injection | The modified EVs accumulated in the liver tissue, resulting in a greater therapeutic effect on liver injury | [128] |
Breast | imDCs | Transfect iRGD peptide binds to the exosomal surface membrane protein Lamp-2b | Dox | – | iRGD-EVs-Dox can be specifically delivered to the breast, playing a highly effective anti-tumor effect | [143] |
Colon | Raw264.7 | Produce HDEA@EVs including PH response HDEA, hyaluronic acid and Dox | Dox | Tail intravenous injection | HDEA@EVs specifically binds to the CD44 receptor on the tumor surface and delivers Dox to colon cancer tumor cells | [144] |